Could anktiva ease long COVID? new safety trial begins
NCT ID NCT07123727
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 32 times
Summary
This study tests the safety of a drug called NAI (Anktiva) in 40 adults aged 18 to 70 who have Long COVID — meaning they still have symptoms after a confirmed COVID-19 infection. The main goal is to check for side effects and changes in vital signs over 30 days after treatment. If safe, this approach might help reduce the burden of lingering COVID symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chan Soon-Schiong Institute for Medicine (CSSIFM)
RECRUITINGEl Segundo, California, 90245, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.